Emmaus life sciences, inc. (MYND)
CashFlow / Yearly
Sep'18Sep'17Sep'16Sep'15Sep'14Sep'13Sep'12Sep'11Sep'10
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss

-10,333

-7,112

-

-

-

-

-

-

-

Net loss

-

-

-5,940

-3,379

-2,662

-10,907

-3,406

-8,866

-8,174

Adjustments to reconcile net loss to net cash flows from operating activities
Valuation of warrants - investor relations

-

-

-

-

0

-

-

-

-

Net loss from discontinued operations

-

-

-

-

-

-

-

538

-

Depreciation and amortization

-

-

-

-

-

13

18

11

9

Amortization of discount of notes payable and convertible notes payable

82

0

-

-

5

662

3,544

4,197

335

Extinguishment of debt

-

-

-

-

-

-

-

-

-1,094

Issuance of warrants for consulting services

-

-

-

-

-

-

-

-

199

Issuance of warrants for financing services

-

-

-

-

-

30

56

183

193

Loss on derivative liability valuation

-

-

-

-

-

-97

6,950

6,826

0

Share-based compensation

1,588

2,086

834

241

1,008

1,257

1,350

1,605

1,302

Net loss from discontinued operations

-

-

-

-

-2

-19

-490

-

-

Depreciation and amortization

117

48

7

7

10

-

-

-

-

Change in provision for doubtful accounts

0

0

-

-

-

-

-

-

12

Gain on derivative liability valuation

-

-

-

-

26

-

-

-

-

Notes conversion expense

-

-

-

-

-

5,792

0

-

-

Common stock issued to vendors for services

-201

-173

0

-

-

-

-

-

-

Change in fair value of embedded conversion option

-

-

-34

162

-

-

-

-

-

Loss on extinguishment of debt

-

-

572

-630

1,105

556

0

-

-

Financing expenses

-

-

-2,717

-275

-

-

-

-

-

Note issued for litigation settlement

-

-

50

-

-

-

-

-

-

Non-cash interest expense

-

-

-

-

2

-

-

-

-

Extinguishment of debt

-

-

-

-

-

-

-

1,968

-

Reversal of prior period accruals

-

-

-

-

-

-

-

-458

-

Non-cash interest expense

-

-

-

-

-

622

664

3,366

21

Net changes in operating assets and liabilities
Accounts receivable

0

1

-6

2

-17

14

-6

-8

0

Prepaid expenses and other current assets

91

12

-25

4

-5

20

-28

-13

-4

Accounts payable and accrued expenses

-432

301

-182

-64

-153

-63

1,386

640

231

Deferred revenue

113

0

-

-

-

-

-

-

-

Accrued compensation and others

-

-

-

-

-

0

469

-

-

Accrued patient costs

-

-

-

-

-

-

-

-

-170

Security deposits

-

-

-9

-

-

0

4

3

-14

Deferred revenue grant funds

-

-

-

-

45

-

-

-

-

Deferred compensation

-285

-275

51

302

-421

30

0

49

43

Net cash flows used in operating activities

-9,038

-4,792

-2,978

-

-

-3,036

-2,337

-3,565

-4,910

CASH FLOWS FROM INVESTING ACTIVITIES
Net cash used in operating activities

-

-

-

-2,156

-3,271

-

-

-

-

Purchases of property and equipment

55

127

4

0

-

-

-

-

-

Purchase of marketable securities and investment at cost

0

190

0

-

-

-

-

-

-

Payment for acquisition of business, net of cash acquired

306

0

-

-

-

-

-

-

-

Loan Advance - Plotkin

0

159

-

-

-

-

-

-

-

Loan Advance- Plotkin

-

-

0

-

-

-

-

-

-

Disposal of equipment

-

-

-

1

0

-

-

-

-

Purchase of intangible assets

0

2

78

0

-

0

21

0

-

Acquisition of furniture & equipment

-

-

-

-

-

0

4

21

14

Disposal of equipment

-

-

-

-

-

1

0

-

-

Net cash flows provided by (used in) investing activities

-361

-479

-82

-

-

1

-25

-21

-14

CASH FLOWS FROM FINANCING ACTIVITIES
Principal payments on long-term debt

37

0

-

-

-

-

-

-

-

Net cash used in investing activities

-

-

-

1

0

-

-

-

-

Principal payments on note payable

-36

-56

0

-

-

-

-

-

-

Repayment of convertible debt with accrued interest

-

-

-

-

-

-

-

-15

0

Repayment of debt

-

-

-

-

-

-

-

26

94

Principal payments on capital lease

2

1

3

3

7

4

6

6

1

Proceeds from Aspire Capital purchase agreements

4,260

145

-

-

-

-

-

-

-

Proceeds from sale of preferred stock and common stock warrants

2,037

0

-

-

-

-

-

-

-

Proceeds from notes payable issued, net of issuance cost and discount

-

-

-

-

-

1,368

2,595

0

-

Proceeds from issuance of common stock

930

2,981

0

-

1,691

2,958

0

0

2,995

Proceeds from public offering

0

7,482

0

-

-

-

-

-

-

Proceeds from stock options exercised

54

0

-

-

-

-

-

-

-

Deferred offering costs

0

148

-

-

-

-

-

-

-

Proceeds from Aspire Line

-

-

0

-

-

-

-

-

-

Offering costs- Aspire Line

-

-

0

-

-

-

-

-

-

Proceeds from sale of common stock

-

-

2,950

1,350

-

-

-

-

-

Net proceeds from sale of bridge notes

-

-

-

-

1,648

-

-

-

-

Net cash provided by financing activities

-

-

-

1,346

3,332

-

-

-

-

Net proceeds from secured convertible notes

-

-

-

-

-

-

-

1,840

1,000

Net proceeds from subordinated convertible notes

-

-

-

-

-

-

-

2,395

0

Net proceeds from unsecured convertible notes

-

-

-

-

-

-

-

0

-

Net proceeds from unperfected senior convertible promissory notes

-

-

-

-

-

-

-

0

-

Proceeds from related party loan

-

-

-

-

-

-

-

-

100

Net cash flows provided by (used in) financing activities

7,206

10,402

2,946

-

-

4,322

2,590

4,218

3,999

Net cash (used in) provided by continuing operations

-

-

-

-

61

1,287

227

-

-

Net cash used in discontinued operations

-

-

-

-

-94

-

-

-613

-

Net Cash used in discontinued operations

-

-

-

-

-

-21

-293

-613

-

NET DECREASE IN CASH

-2,194

5,130

-113

-808

-33

1,265

-65

18

-926

SUPPLEMENTAL DISCLOSURES OF CASH FLOW ACTIVITIES
Interest paid

8

6

4

3

4

3

9

3

7

Finance Fees

-

-

20

0

-

-

-

-

-

Income taxes paid

1

2

2

4

5

0

1

1

0

Long-term borrowings assumed in business combination

651

0

-

-

-

-

-

-

-

Commitment shares issued to Aspire Capital as offering cost

795

708

-

-

-

-

-

-

-

Investment in Arcadian 1,000 shares at $5.90 per share of common stock

0

5

-

-

-

-

-

-

-

Investment in Arcadian 1,000 shares @ $5.90 per share of common stock

-

-

0

-

-

-

-

-

-

Conversion of convertible notes to common stock

-

-

6,266

-

-

-

-

-

-

Conversion of Brandt litigation settlement convertible note to common stock

-

-

50

-

-

-

-

-

-

Shares issued for extinguishment of liabilities

-

-

-

-

361

-

-

-

-

Shares issued for cashless exercise of warrants

-

-

-

-

0

-

-

-

-

Fair value of note payable to officer issued for acquisition

-

-

-

-

-

-

-

-

24

Fair value of intellectual property

-

-

-

-

-

-

-

16

6

Offering costs

-

-

-

-

-

2

784

103

-

Shares issued for converting bridge note

-

-

-

-

-

-

-

0

-

Offering costs

-

-

-

-

-

2

784

103

-

Shares issued for officer salaries

-

-

-

-

-

7

0

-

-

Shares issued on conversion of promissory notes and accrued interest

-

-

-

-

-

11,273

0

-

-

Shares issued for accounts payable

-

-

-

-

-

502

0

44

-

Fair value of intellectual property

0

2

78

-

-

-

-

-

-

Shares issued for accounts payable

-

-

-

-

-

-

-

-

0